首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1572509

非酒精性脂肪性肝炎治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Non-alcoholic Steatohepatitis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 159 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球非酒精性脂肪性肝炎(NASH) 治療市場估值為55 億美元，預計2024 年至2032 年複合年成長率為29.9%。這主要是由於肥胖和 2 型糖尿病發病率不斷上升，並提高了人們對 NASH 作為關鍵健康問題的認知。

世界衛生組織 (WHO) 2022 年的報告指出，全球 43% 的成年人超重，其中 16% 屬於肥胖。這些統計數據凸顯了代謝疾病帶來的全球健康挑戰，包括 NASH 的風險增加。為此，從新藥物療法到強調體重管理的生活方式介入等創新治療策略，加強了患者護理並推動了市場成長。

診斷技術的進步在推動市場方面發揮關鍵作用。增強的醫療技術和診斷方法使醫療保健專業人員能夠更準確地檢測和監測 NASH。這些方法的發展催生了侵入性較小但精確的診斷工具，這對於有效的疾病管理至關重要。美國肝病研究協會 (AASLD) 的報告指出，從 2010 年到 2020 年，非侵入性診斷工具的準確性提高了 40%。

整個非酒精性脂肪性肝炎治療產業根據藥物類型、給藥途徑、配銷通路和地區進行分類。

維生素 E 和吡格列酮細分市場到 2023 年的市場佔有率將達到 17 億美元。噻唑烷二酮類藥物吡格列酮顯示出良好的前景，特別是對於患有第 2 型糖尿病的 NASH 患者。維生素 E 的實惠性和安全性使其成為 NASH 患者的首選推薦，進一步推動市場成長。此外，吡格列酮能夠提高 NASH 患者（尤其是糖尿病患者）的胰島素敏感性並改善肝臟組織學，這凸顯了其重要性。

到 2023 年，零售和專業藥房領域的銷售額將達到 27 億美元。零售藥局通常是患者的初步接觸點，為疲勞等 NASH 症狀提供非處方藥和處方藥解決方案。它們在確保可近性和可負擔性方面的作用對於 NASH 等慢性病至關重要。專業藥局專注於複雜藥物，提供個人化服務，包括病患教育，這對於掌握 NASH 複雜的治療方案至關重要。

北美 NASH 治療市場預計將以 28.4% 的複合年成長率成長，到 2032 年將達到 232 億美元。美國國家糖尿病、消化和腎臟疾病研究所 (NIDDK) 的數據顯示，大約 24% 的美國成年人患有 NAFLD，其中 1.5% 至 6.5% 被診斷為 NASH。如果未經治療，NASH 會帶來嚴重的風險，包括肝硬化和肝癌。影響因素包括肥胖率上升、2 型糖尿病病例激增以及久坐的生活方式。市場的研發工作也顯著增加，凸顯了對有效治療方法的追求。

產業生態系統分析
產業影響力
- 成長動力
  - 診斷技術的進步
  - NASH 盛行率增加
  - 提高對 NASH 的認知和診斷
- 產業陷阱與挑戰
  - 治療費用高
  - 副作用和安全問題
成長潛力分析
監管環境
管道分析
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

主要趨勢
維生素E和吡格列酮
奧貝膽酸 (OCA)
索馬魯肽
塞隆塞提布
塞尼奇韋羅
其他藥物類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
口服
可注射

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

主要趨勢
醫院藥房
零售和專業藥局
其他分銷管道

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AstraZeneca
Bristol-Myers Squibb Company
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Genfit
Gilead Sciences, Inc.
Immuron Ltd
Intercept Pharmaceuticals, Inc.
Madrigal Pharmaceuticals
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Zydus Cadila

簡介目錄

Product Code: 10894

The Global Non-alcoholic Steatohepatitis (NASH) Treatment Market was valued at USD 5.5 billion in 2023 and is projected to expand at a CAGR of 29.9% from 2024 to 2032. The market is driven by the rising prevalence of metabolic disorders, largely due to increasing obesity and type 2 diabetes rates, and heightened awareness of NASH as a critical health concern.

A 2022 report from the World Health Organization (WHO) noted that 43% of adults globally were overweight, with 16% classified as obese. These statistics highlight the global health challenge posed by metabolic diseases, including the heightened risk of developing NASH. In response, innovative treatment strategies, from new drug therapies to lifestyle interventions emphasizing weight management, bolster patient care and fuel market growth.

Advancements in diagnostic techniques play a pivotal role in propelling the market. Enhanced medical technologies and diagnostic methods empower healthcare professionals to detect and monitor NASH with greater accuracy. The evolution of these methods has birthed less invasive yet precise diagnostic tools, essential for effective disease management. A report from the American Association for the Study of Liver Diseases (AASLD) noted a 40% improvement in the accuracy of non-invasive diagnostic tools from 2010 to 2020.

The overall non-alcoholic steatohepatitis treatment industry is divided based on drug type, route of administration, distribution channel, and region.

The vitamin E and Pioglitazone segment commanded a market share of USD 1.7 billion in 2023. Vitamin E's antioxidant properties play a crucial role in treating NASH, helping to alleviate liver inflammation. Pioglitazone, from the thiazolidinedione class, shows promise, especially for NASH patients with type 2 diabetes. Its affordability and safety make vitamin E a go-to recommendation for NASH patients, further driving market growth. Additionally, pioglitazone's ability to boost insulin sensitivity and improve liver histology in NASH patients, especially diabetics, underscores its significance.

The retail and specialty pharmacies segment accounted for USD 2.7 billion in 2023. As NASH prevalence surges, driven by global obesity trends and metabolic syndrome incidences, the demand for effective therapies has skyrocketed. Retail pharmacies often serve as the initial touchpoint for patients, offering both over-the-counter and prescription solutions for NASH symptoms like fatigue. Their role in ensuring accessibility and affordability is vital for chronic conditions like NASH. Specialty pharmacies, focusing on complex medications, offer personalized services, including patient education, crucial for navigating NASH's intricate treatment regimens.

Projected to grow at a CAGR of 28.4%, North America NASH treatment market is set to reach USD 23.2 billion by 2032. The U.S. market expansion is closely tied to the rising NASH prevalence. Data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reveals that approximately 24% of U.S. adults have NAFLD, with 1.5% to 6.5% diagnosed with NASH. Untreated, NASH poses severe risks, including cirrhosis and liver cancer. Contributing factors include escalating obesity rates, a surge in type 2 diabetes cases, and increasingly sedentary lifestyles. The market also sees a notable uptick in research and development endeavors, underscoring the quest for effective treatments.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in diagnostic techniques
  - 3.2.1.2 Increasing prevalence of NASH
  - 3.2.1.3 Growing awareness and diagnosis of NASH
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Vitamin E and pioglitazone
5.3 Obeticholic acid (OCA)
5.4 Semaglutide
5.5 Selonsertib
5.6 Cenicriviroc
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail and specialty pharmacies
7.4 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa